Sanofi (FRA:SNW)
85.34
+0.81 (0.96%)
Last updated: Sep 3, 2025, 2:19 PM CET
Sanofi Revenue
Sanofi had revenue of 10.74B EUR in the quarter ending June 30, 2025. This brings the company's revenue in the last twelve months to 45.74B, up 15.65% year-over-year. In the year 2024, Sanofi had annual revenue of 44.29B with 7.73% growth.
Revenue (ttm)
45.74B
Revenue Growth
+15.65%
P/S Ratio
2.25
Revenue / Employee
551.87K
Employees
82,878
Market Cap
103.06B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 44.29B | 3.18B | 7.73% |
Dec 31, 2023 | 41.11B | 805.00M | 2.00% |
Dec 31, 2022 | 40.30B | 1.13B | 2.88% |
Dec 31, 2021 | 39.18B | 1.81B | 4.83% |
Dec 31, 2020 | 37.37B | -262.00M | -0.70% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
SAP SE | 35.89B |
Siemens Aktiengesellschaft | 78.30B |
Deutsche Telekom AG | 120.55B |
Allianz SE | 109.02B |
Rheinmetall AG | 10.67B |
Siemens Energy AG | 38.39B |
Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 62.33B |
Deutsche Bank Aktiengesellschaft | 30.07B |
Sanofi News
- 18 hours ago - Sanofi (SNY) Receives Upgrade from Deutsche Bank | SNY Stock News - GuruFocus
- 1 day ago - Sanofi CEO: AI might beat IQ, not EQ — but never say never - Fortune
- 1 day ago - Thermo Fisher Scientific Completes Acquisition of Sanofi’s Ridgefield, New Jersey Site - Wallstreet:Online
- 3 days ago - Sanofi's (SNY) Wayrilz Gains FDA Approval for ITP Treatment - GuruFocus
- 3 days ago - Sanofi wins FDA nod for Wayrilz in bleeding disorder thrombocytopenia - Seeking Alpha
- 3 days ago - Now Is The Time To Buy This High-Yielding Trio - Seeking Alpha
- 4 days ago - US FDA approves Sanofi's drug for a rare blood disorder - Reuters
- 4 days ago - Press Release: Sanofi's Wayrilz approved in US as first BTK inhibitor for immune thrombocytopenia - Benzinga